TwinBeech Capital’s Ionis Pharmaceuticals IONS Stock Holding History

TwinBeech Capital’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,938	Closed	-$481K	–	811
2025 Q1	$481K	Buy	+15,938	New	+$522K	0.01%	580
2024 Q4	–	Sell	-235,477	Closed	-$9.43M	–	763
2024 Q3	$9.43M	Buy	+235,477	New	+$11M	0.18%	150
2024 Q2	–	Sell	-46,364	Closed	-$2.01M	–	659
2024 Q1	$2.01M	Buy	46,364 +16,635	+56%	+$793K	0.04%	342
2023 Q4	$1.5M	Buy	+29,729	New	+$1.42M	0.02%	443
2023 Q2	–	Sell	-136,967	Closed	-$4.9M	–	729
2023 Q1	$4.9M	Buy	+136,967	New	+$5.14M	0.1%	246
2021 Q2	–	Sell	-22,750	Closed	-$1.02M	–	543
2021 Q1	$1.02M	Buy	+22,750	New	+$1.27M	0.15%	190
2020 Q4	–	Sell	-4,872	Closed	-$231K	–	513
2020 Q3	$231K	Buy	+4,872	New	+$271K	0.05%	376

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TwinBeech Capital's IONS Position: Q2 2025 in Review

TwinBeech Capital sold out of Ionis Pharmaceuticals (IONS) in Q2 2025, closing a stake of 15,938 shares — an estimated $481K sold.

TwinBeech Capital first reported a position in IONS in Q3 2020 and held it in 7 quarters. The position peaked at $9.43M in Q3 2024. 362 funds tracked by Wall St. Rank hold IONS as of Q2 2025.

TwinBeech Capital reported no remaining Ionis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
TwinBeech Capital sold 15,938 Ionis Pharmaceuticals shares in Q2 2025, an estimated $481K.
TwinBeech Capital first reported a position in Ionis Pharmaceuticals in Q3 2020 and held it in 7 quarters.
TwinBeech Capital's Ionis Pharmaceuticals position peaked at $9.43M in Q3 2024.
362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2025.

Based on TwinBeech Capital's 13F filing for Q2 2025, filed 14 Aug 2025.